Kindred Companion Sciences bred two beagles without the major dog allergen in the second year since their creation in September 2024, but the FDA hasn't approved the company's gene-editing tools. Bailey and Alfie represent a significant leap in biotechnology—yet they also expose a widening gap between what science can do and who gets to benefit.
The company used CRISPR-based precision gene editing to eliminate Can f 1, the primary allergen found in dog dander and saliva. Veterinary examinations show both dogs are developing normally, even though regulatory approval remains pending. The genetic editing was conducted in accordance with U.S. federal standards for animal care and use, the company said.
Dog and cat allergies affect 10% to 20% of the worldwide population, according to National Institutes of Health information cited in USA TODAY's August 7, 2026 report. That's roughly 800 million to 1.6 billion people globally who experience discomfort, medical expenses, and lifestyle restrictions because of a common health problem.
The Limits of Current Solutions
For decades, people with allergies have relied on management strategies that don't address the root cause. Existing approaches focus primarily on controlling the body's immune response rather than reducing allergen production at its source. A March 2024 study published by the National Institutes of Health confirmed what many suspected: no dog, cat, or horse breed is completely hypoallergenic.
The company's own August study underscores this reality. "Breeds marketed as hypoallergenic do not yield consistently lower environmental exposure," the research states. "These approaches do not alter the underlying expression of Can f 1, which is produced from sebaceous glands and tongue epithelial tissue." Sebaceous glands are oil-producing glands found on the skin; tongue epithelial tissue is the tongue's outer layer of cells. Marketing claims about hypoallergenic dogs have misled consumers for years while doing nothing to address the actual problem.
The Obama family's experience illustrates the gap between wealth and access. Bo and Sunny, Portuguese Water Dogs, joined the Obamas in 2009 and 2013 after Malia Obama, President Barack Obama's eldest daughter, suffered from canine allergies. The family could afford a rare breed marketed as hypoallergenic. Most families cannot.
The Broader Gene-Editing Frontier
Kindred's work reflects a wider trend in animal genetic engineering. Colossal Biosciences, a Texas-based company, announced last year that it had brought the dire wolf back from extinction, breeding three dire wolf puppies using extracted DNA from a 13,000-year-old tooth and a 72,000-year-old skull. Researchers used DNA specimens of the extinct animal to create two dire wolf genomes and compare them with other canid species, then edited 14 genes found in modern gray wolves to match specific extinct traits. Domestic dogs served as surrogate mothers for the wolves.
The dire wolf previously existed only 13,000 years ago, stood about 3½ feet tall, and could weigh up to 150 pounds. Its resurrection raises profound questions about the purpose and limits of genetic technology.
Why This Matters:
Gene-edited allergy-free dogs could transform life for millions of people with allergies—but only if the technology becomes accessible and affordable. Right now, it exists in a regulatory void. Without FDA approval and oversight, there's no guarantee these dogs will be safe for long-term ownership, nor any assurance that the benefits will reach beyond wealthy early adopters. The success of Bailey and Alfie doesn't solve the public health problem; it highlights how technological breakthroughs can deepen inequality when they're controlled by private companies and available only to those who can pay premium prices. The question isn't whether gene editing works—it's who gets to use it, under what rules, and whether society will ensure the benefits reach the people who need them most.